In vivo administration of corticotropin-releasing hormone at remote intervals following ischemia enhances CA1 neuronal survival and recovery of spatial memory impairments: A role for opioid receptors

Behavioural Brain Research

Volumn 188, Issue 1, 2008, Pages 125-135

  Charron, Charlaine ^a   Fréchette, Sabrina ^a   Proulx, Geneviève ^a   Plamondon, Hélène ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Helical CRH; CRH; Hippocampus; Neuronal protection; Opioids; Spatial memory

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; DELTA OPIATE RECEPTOR ANTAGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE RECEPTOR;

ALPHA HELIX; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CELL SURVIVAL; CONTROLLED STUDY; HIPPOCAMPUS; IN VIVO STUDY; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; STATISTICAL SIGNIFICANCE; WISTAR RAT;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN ISCHEMIA; CELL DEATH; CORTICOTROPIN-RELEASING HORMONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HIPPOCAMPUS; INJECTIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; TIME FACTORS;

EID: 38749131638     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2007.10.027     Document Type: Article

References (67)

1. Babcock A.M., Baker D.A., and Lovec R. Locomotor activity in the ischemic gerbil. Brain Res 625 (1993) 351-354
2. Bayatti N., Zschocke J., and Behl C. Brain region-specific neuroprotective action and signaling of corticotropin-releasing hormone in primary neurons. Endocrinology 144 (2003) 4051-4060
3. Belcheva M.M., Tan Y., Heaton V.M., Clark A.L., and Coscia C.J. Mu opioid transactivation and down-regulation of the epidermal growth factor receptor in astrocytes: implications for mitogen-activated protein kinase signaling. Mol Pharmacol 64 (2003) 1391-1401
4. Block F., and Schwarz M. Global ischemic neuronal damage relates to behavioural deficits: a pharmacological approach. Neuroscience 82 (1998) 791-803
5. Boutin H., Dauphin F., MacKenzie E.T., and Jauzac P. Differential time-course decreases in nonselective, mu-, delta-, and kappa-opioid receptors after focal cerebral ischemia in mice. Stroke 30 (1999) 1271-1277
6. Boutin H., Jauzac P., MacKenzie E.T., and Dauphin F. Maximal densities of mu, delta, and kappa receptors are differentially altered by focal cerebral ischaemia in the mouse. Brain Res 787 (1998) 237-241
7. Boutin H., Jauzac P., MacKenzie E.T., and Dauphin F. Potential use of early alterations in mu and delta opioid receptors as a predictive index for delayed brain ischemic damage. Neurobiol Dis 13 (2003) 63-73
8. Braida D., Paladini E., Gori E., and Sala M. Naltrexone, naltrindole, and CTOP block cocaine-induced sensitization to seizures and death. Peptides 18 (1997) 1189-1195
9. Cabot P.J., Carter L., Schafer M., and Stein C. Methionine-enkephalin-and Dynorphin A-release from immune cells and control of inflammatory pain. Pain 93 (2001) 207-212
10. Carlsen J., De Olmos J., and Heimer L. Tracing of two-neuron pathways in the olfactory system by the aid of transneuronal degeneration: projections to the amygdaloid body and hippocampal formation. J Comp Neurol 208 (1982) 196-208
11. Ceccatelli S., Eriksson M., and Hokfelt T. Distribution and coexistence of corticotropin-releasing factor-, neurotensin-, enkephalin-, cholecystokinin-, galanin- and vasoactive intestinal polypeptide/peptide histidine isoleucine-like peptides in the parvocellular part of the paraventricular nucleus. Neuroendocrinology 49 (1989) 309-323
12. Choi D.I., Park S.K., Kim H.S., Seo M.O., Kim S.J., Kim J.S., et al. Expression of corticotropin releasing factor, but not its binding protein, in CA1 pyramidal cells of gerbil hippocampus following transient ischemia. Brain Res 899 (2001) 255-259
13. Colbourne F., and Corbett D. Delayed postischemic hypothermia: a six month survival study using behavioral and histological assessments of neuroprotection. J Neurosci 15 (1995) 7250-7260
14. Craighead M.W., Boutin H., Middlehurst K.M., Allan S.M., Brooks N., Kimber I., et al. Influence of corticotrophin releasing factor on neuronal cell death in vitro and in vivo. Brain Res 881 (2000) 139-143
15. Davis H.P., Tribuna J., Pulsinelli W.A., and Volpe B.T. Reference and working memory of rats following hippocampal damage induced by transient forebrain ischemia. Physiol Behav 37 (1986) 387-392
16. Diamant M., and de Wied D. Autonomic and behavioral effects of centrally administered corticotropin-releasing factor in rats. Endocrinology 129 (1991) 446-454
17. Elliott-Hunt C.R., Kazlauskaite J., Wilde G.J., Grammatopoulos D.K., and Hillhouse E.W. Potential signalling pathways underlying corticotrophin-releasing hormone-mediated neuroprotection from excitotoxicity in rat hippocampus. J Neurochem 80 (2002) 416-425
18. Facci L., Stevens D.A., Pangallo M., Franceschini D., Skaper S.D., and Strijbos P.J. Corticotropin-releasing factor (CRF) and related peptides confer neuroprotection via type 1 CRF receptors. Neuropharmacology 45 (2003) 623-636
19. Fanselow M.S., Calcagnetti D.J., and Helmstetter F.J. Role of mu and kappa opioid receptors in conditional fear-induced analgesia: the antagonistic actions of nor-binaltorphimine and the cyclic somatostatin octapeptide, Cys2Tyr3Orn5Pen7-amide. J Pharmacol Exp Ther 250 (1989) 825-830
20. Fryer R.M., Hsu A.K., Eells J.T., Nagase H., and Gross G.J. Opioid-induced second window of cardioprotection: potential role of mitochondrial KATP channels. Circ Res 84 (1999) 846-851
21. Gionet T.X., Thomas J.D., Warner D.S., Goodlett C.R., Wasserman E.A., and West J.R. Forebrain ischemia induces selective behavioral impairments associated with hippocampal injury in rats. Stroke 22 (1991) 1040-1047
22. Goyagi T., Toung T.J., Kirsch J.R., Traystman R.J., Koehler R.C., Hurn P.D., et al. Neuroprotective kappa-opioid receptor agonist BRL 52537 attenuates ischemia-evoked nitric oxide production in vivo in rats. Stroke 34 (2003) 1533-1538
23. Hall E.D., and Pazara K.E. Quantitative analysis of effects of kappa-opioid agonists on postischemic hippocampal CA1 neuronal necrosis in gerbils. Stroke 19 (1988) 1008-1012
24. Heinrichs S.C., Britton K.T., and Koob G.F. Both conditioned taste preference and aversion induced by corticotropin-releasing factor. Pharmacol Biochem Behav 40 (1991) 717-721
25. Hendryk S., Jedrzejowska-Szypulka H., Josko J., Jarzab B., and Dohler K.D. Influence of the corticotropin releasing hormone (CRH) on the brain-blood barrier permeability in cerebral ischemia in rats. J Physiol Pharmacol 53 (2002) 85-94
26. Heurteaux C., Bertaina V., Widmann C., and Lazdunski M. K+ channel openers prevent global ischemia-induced expression of c-fos, c-jun, heat shock protein, and amyloid beta-protein precursor genes and neuronal death in rat hippocampus. Proc Natl Acad Sci USA 90 (1993) 9431-9435
27. Joels M. Corticosteroid effects in the brain: U-shape it. Trends Pharmacol Sci 27 (2006) 244-250
28. Kang Y.M., Zhang Z.H., Johnson R.F., Yu Y., Beltz T., Johnson A.K., et al. Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure. Circ Res 99 (2006) 758-766
29. Khan S., Milot M., Lecompte-Collin J., and Plamondon H. Time-dependent changes in CRH concentrations and release in discrete brain regions following global ischemia: effects of MK-801 pretreatment. Brain Res 1016 (2004) 48-57
30. Kirino T., Tsujita Y., and Tamura A. Induced tolerance to ischemia in gerbil hippocampal neurons. J Cereb Blood Flow Metab 11 (1991) 299-307
31. Kishi T., Tsumori T., Yokota S., and Yasui Y. Topographical projection from the hippocampal formation to the amygdala: a combined anterograde and retrograde tracing study in the rat. J Comp Neurol 496 (2006) 349-368
32. Kiyota Y., Miyamoto M., and Nagaoka A. Relationship between brain damage and memory impairment in rats exposed to transient forebrain ischemia. Brain Res 538 (1991) 295-302
33. Kusumoto K., MacKay K.B., and McCulloch J. The effect of the kappa-opioid receptor agonist CI-977 in a rat model of focal cerebral ischaemia. Brain Res 576 (1992) 147-151
34. Lemere C.A. A beneficial role for IL-1 beta in Alzheimer disease?. J Clin Invest 117 (2007) 1483-1485 [comment]
35. Lezoualc'h F., Engert S., Berning B., and Behl C. Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappaB. Mol Endocrinol 14 (2000) 147-159
36. Lyons M.K., Anderson R.E., and Meyer F.B. Corticotropin releasing factor antagonist reduces ischemic hippocampal neuronal injury. Brain Res 545 (1991) 339-342
37. Mansour A., Burke S., Pavlic R.J., Akil H., and Watson S.J. Immunohistochemical localization of the cloned kappa 1 receptor in the rat CNS and pituitary. Neuroscience 71 (1996) 671-690
38. Maya-Nunez G., Castro-Fernandez C., and Mendez J.P. Maya-Nunez G, Castro-Fernandez C, Mendez JP. CRH-stimulation of cyclic adenosine 5′-monophosphate pathway is partially inhibited by the coexpression of CRH-R1 and CRH-R2alpha [erratum appears in Endocrine 2005;27(August (3)):311]. Endocrine 27 (2005) 67-73
39. Nelson A., Lebessi A., Sowinski P., and Hodges H. Comparison of effects of global cerebral ischaemia on spatial learning in the standard and radial water maze: relationship of hippocampal damage to performance. Behav Brain Res 85 (1997) 93-115
40. Ochedalski T., Rabadan-Diehl C., Aguilera G., Ochedalski T., Rabadan-Diehl C., and Aguilera G. Interaction between glucocorticoids and corticotropin releasing hormone (CRH) in the regulation of the pituitary CRH receptor in vivo in the rat. J Neuroendocrinol 10 (1998) 363-369
41. Okubo S., Tanabe Y., Takeda K., Kitayama M., Kanemitsu S., Kukreja R.C., et al. Ischemic preconditioning and morphine attenuate myocardial apoptosis and infarction after ischemia-reperfusion in rabbits: role of delta-opioid receptor. Am J Physiol Heart Circ Physiol 287 (2004) H1786-H1791
42. Olsen G.M., Scheel-Kruger J., Moller A., and Jensen L.H. Does neuronal damage of CA1 relate to spatial memory performance of rats subjected to transient forebrain ischemia?. Acta Neurol Scand 89 (1994) 204-209
43. Patel H.H., Hsu A.K., and Gross G.J. COX-2 and iNOS in opioid-induced delayed cardioprotection in the intact rat. Life Sci 75 (2004) 129-140
44. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1986), Academic Press, San Diego
45. Pedersen W.A., McCullers D., Culmsee C., Haughey N.J., Herman J.P., and Mattson M.P. Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer's disease. Neurobiol Dis 8 (2001) 492-503
46. Pedersen W.A., Wan R., Zhang P., and Mattson M.P. Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I. J Neurosci 22 (2002) 404-412
47. Plamondon H., Blondeau N., Heurteaux C., and Lazdunski M. Mutually protective actions of kainic acid epileptic preconditioning and sublethal global ischemia on hippocampal neuronal death: involvement of adenosine A1 receptors and K(ATP) channels. J Cereb Blood Flow Metab 19 (1999) 1296-1308
48. Plamondon H., and Khan S. Characterization of anxiety and habituation profile following global ischemia in rats. Physiol Behav 84 (2005) 543-552
49. Plamondon H., and Khan S. The CRH1 antagonist CP154,526 failed to alter ischemia-induced neurodegeneration and spatial memory deficits in rats but inhibited behavioral activity in the novel open field. Behav Brain Res 166 (2006) 85-92
50. Pretel S., and Piekut D. Coexistence of corticotropin-releasing factor and enkephalin in the paraventricular nucleus of the rat. J Comp Neurol 294 (1990) 192-201
51. Prut L., and Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463 (2003) 3-33
52. Pulsinelli W.A., and Brierley J.B. A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke 10 (1979) 267-272
53. Radulovic M., Hippel C., and Spiess J. Corticotropin-releasing factor (CRF) rapidly suppresses apoptosis by acting upstream of the activation of caspases. J Neurochem 84 (2003) 1074-1085
54. Rivier C., Rivier J., and Lee S. Importance of pituitary and brain receptors for corticotrophin-releasing factor in modulating alcohol-induced ACTH secretion in the rat. Brain Res 721 (1996) 83-90
55. Romeo R.D., Mueller A., Sisti H.M., Ogawa S., McEwen B.S., and Brake W.G. Anxiety and fear behaviors in adult male and female C57BL/6 mice are modulated by maternal separation. Horm Behav 43 (2003) 561-567
56. Rotllant D., and Armario A. A single dose of metyrapone caused long-term dysregulation of the hypothalamic-pituitary-adrenal axis in the rat. Neuroscience 130 (2005) 427-434
57. Schafer M., Carter L., and Stein C. Interleukin 1 beta and corticotropin-releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue. Proc Natl Acad Sci USA 91 (1994) 4219-4223
58. Schultz J.J., Hsu A.K., and Gross G.J. Ischemic preconditioning and morphine-induced cardioprotection involve the delta (delta)-opioid receptor in the intact rat heart. J Mol Cell Cardiol 29 (1997) 2187-2195
59. Shaftel S.S., Carlson T.J., Olschowka J.A., Kyrkanides S., Matousek S.B., O'Banion M.K., et al. Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J Neurosci 27 (2007) 9301-9309
60. Shibahara S., Morimoto Y., Furutani Y., Notake M., Takahashi H., Shimizu S., et al. Isolation and sequence analysis of the human corticotropin-releasing factor precursor gene. EMBO J 2 (1983) 775-779
61. Smith-Swintosky V.L., Pettigrew L.C., Sapolsky R.M., Phares C., Craddock S.D., Brooke S.M., et al. Metyrapone, an inhibitor of glucocorticoid production, reduces brain injury induced by focal and global ischemia and seizures. J Cereb Blood Flow Metab 16 (1996) 585-598
62. Song C., Li X., Leonard B.E., and Horrobin D.F. Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. J Lipid Res 44 (2003) 1984-1991
63. Strijbos P.J., Relton J.K., and Rothwell N.J. Corticotrophin-releasing factor antagonist inhibits neuronal damage induced by focal cerebral ischaemia or activation of NMDA receptors in the rat brain. Brain Res 656 (1994) 405-408
64. Tjoumakaris S.I., Rudoy C., Peoples J., Valentino R.J., and Van Bockstaele E.J. Cellular interactions between axon terminals containing endogenous opioid peptides or corticotropin-releasing factor in the rat locus coeruleus and surrounding dorsal pontine tegmentum. J Comp Neurol 466 (2003) 445-456
65. Wang D., and Corbett D. Cerebral ischemia, locomotor activity and spatial mapping. Brain Res 533 (1990) 78-82
66. Wong M.L., Loddick S.A., Bongiorno P.B., Gold P.W., Rothwell N.J., and Licinio J. Focal cerebral ischemia induces CRH mRNA in rat cerebral cortex and amygdala. Neuroreport 6 (1995) 1785-1788
67. Zhang J., Gibney G.T., Zhao P., and Xia Y. Neuroprotective role of delta-opioid receptors in cortical neurons. Am J Physiol Cell Physiol 282 (2002) C1225-C1234